Dec 18 (Reuters) - Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. (Reporting by Mariam Sunny in Bengaluru)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.9 USD | +0.53% | +3.26% | -17.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.03% | 70.02M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- CKPT Stock
- News Checkpoint Therapeutics, Inc.
- US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy